{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:47:57Z","timestamp":1787060877940,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12185-020-02872-3","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T05:29:58Z","timestamp":1589866198000},"page":"238-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myeloid neoplasm with isolated del(5q) and the MPLW515L mutation fulfills the WHO diagnostic criteria for ET"],"prefix":"10.1007","volume":"112","author":[{"given":"Keita","family":"Kirito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"6","key":"2872_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379. https:\/\/doi.org\/10.1182\/blood-2016-10-695940.","journal-title":"Blood"},{"issue":"1","key":"2872_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ajh.24253","volume":"91","author":"N Gangat","year":"2016","unstructured":"Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016;91(1):76\u201389. https:\/\/doi.org\/10.1002\/ajh.24253.","journal-title":"Am J Hematol"},{"issue":"7","key":"2872_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/sj.leu.2404215","volume":"20","author":"W Ingram","year":"2006","unstructured":"Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow [14]. Leukemia. 2006;20(7):1319\u201321. https:\/\/doi.org\/10.1038\/sj.leu.2404215.","journal-title":"Leukemia"},{"issue":"5","key":"2872_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ajh.21984","volume":"86","author":"MM Patnaik","year":"2011","unstructured":"Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, et al. Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol. 2011;86(5):393\u20138. https:\/\/doi.org\/10.1002\/ajh.21984.","journal-title":"Am J Hematol"},{"issue":"9","key":"2872_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2017.166173","volume":"102","author":"M Meggendorfer","year":"2017","unstructured":"Meggendorfer M, Haferlach C, Kern W, Haferlach T. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. Haematologica. 2017;102(9):1502\u201310. https:\/\/doi.org\/10.3324\/haematol.2017.166173.","journal-title":"Haematologica"},{"issue":"3","key":"2872_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.humpath.2012.05.022","volume":"44","author":"JT Geyer","year":"2013","unstructured":"Geyer JT, Verma S, Mathew S, Wang YL, Racchumi J, Espinal-Witter R, et al. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Hum Pathol. 2013;44(3):346\u201356. https:\/\/doi.org\/10.1016\/j.humpath.2012.05.022.","journal-title":"Hum Pathol"},{"key":"2872_CR7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227686","author":"VFI Sangiorgio","year":"2019","unstructured":"Sangiorgio VFI, Geyer JT, Margolskee E, Al- Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a grey zone combination of myelodysplastic and myeloproliferative features? Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2019.227686.","journal-title":"Haematologica"},{"issue":"1","key":"2872_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cancergencyto.2010.04.019","volume":"201","author":"KF Wong","year":"2010","unstructured":"Wong KF, Yu PH, Wong WS. Essential thrombocythemia with deleted 5q - a genetic and morphologic hybrid? Cancer Genet Cytogenet. 2010;201(1):39\u201341. https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.04.019.","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2872_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.leukres.2009.09.016","volume":"34","author":"L Sokol","year":"2010","unstructured":"Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res. 2010;34(6):821\u20133. https:\/\/doi.org\/10.1016\/j.leukres.2009.09.016.","journal-title":"Leuk Res"},{"key":"2872_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lrr.2018.08.001","volume":"10","author":"A Alshaban","year":"2018","unstructured":"Alshaban A, Padilla O, Philipovskiy A, Corral J, McAlice M, Gaur S. Lenalidomide induced durable remission in a patient with MDS\/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome. Leuk Res Rep. 2018;10:37\u201340. https:\/\/doi.org\/10.1016\/j.lrr.2018.08.001.","journal-title":"Leuk Res Rep"},{"issue":"4","key":"2872_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s12185-009-0411-5","volume":"90","author":"M Sever","year":"2009","unstructured":"Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, et al. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009;90(4):522\u20135. https:\/\/doi.org\/10.1007\/s12185-009-0411-5.","journal-title":"Int J Hematol"},{"issue":"4","key":"2872_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \"atypical\" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207\u20139. https:\/\/doi.org\/10.1182\/blood-2005-03-1183.","journal-title":"Blood"},{"issue":"7","key":"2872_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/leu.2010.105","volume":"24","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, et al. WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2. MPL and IDH Mutations Leuk. 2010;24(7):1283\u20139. https:\/\/doi.org\/10.1038\/leu.2010.105.","journal-title":"MPL and IDH Mutations Leuk"},{"issue":"10","key":"2872_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3109\/10428194.2010.506567","volume":"51","author":"G Azaceta","year":"2010","unstructured":"Azaceta G, Calasanz MJ, Dourdil V, Bonafonte E, Izquierdo I, Palomera L. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. Leuk Lymph. 2010;51(10):1941\u20133. https:\/\/doi.org\/10.3109\/10428194.2010.506567.","journal-title":"Leuk Lymph"},{"issue":"9","key":"2872_CR15","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.leukres.2011.06.008","volume":"35","author":"M Nomdedeu","year":"2011","unstructured":"Nomdedeu M, Maffioli M, Calvo X, Mart\u00ednez-Trillos A, Baumann T, D\u00edaz-Bey\u00e1 M, et al. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leuk Res. 2011;35(9):1276\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2011.06.008.","journal-title":"Leuk Res"},{"key":"2872_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/OTT.S59628","volume":"7","author":"P Musto","year":"2014","unstructured":"Musto P, Simeon V, Guariglia R, Bianchino G, Grieco V, Nozza F, et al. Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. OncoTargets Ther. 2014;7:1043\u201350. https:\/\/doi.org\/10.2147\/OTT.S59628.","journal-title":"OncoTargets Ther"},{"issue":"1","key":"2872_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/mco.2016.866","volume":"5","author":"E Hatzimichael","year":"2016","unstructured":"Hatzimichael E, Lagos K, Vassou A, Gougopoulou D, Papoudou-Bai A, Briasoulis E. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment. Mol Clin Oncol. 2016;5(1):23\u20136. https:\/\/doi.org\/10.3892\/mco.2016.866.","journal-title":"Mol Clin Oncol"},{"issue":"10","key":"2872_CR18","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1080\/10428194.2017.1295146","volume":"58","author":"S Oka","year":"2017","unstructured":"Oka S, Ono K, Nohgawa M. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide. Leuk Lymph. 2017;58(10):2511\u20133. https:\/\/doi.org\/10.1080\/10428194.2017.1295146.","journal-title":"Leuk Lymph"},{"issue":"1","key":"2872_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood-2018-03-842161","volume":"132","author":"R Tremblay-LeMay","year":"2018","unstructured":"Tremblay-LeMay R, Chang H. Concurrent JAK2 mutation and isolated del(5q) associated with marrow fibrosis and small hypo\/monolobated megakaryocytes. Blood. 2018;132(1):112. https:\/\/doi.org\/10.1182\/blood-2018-03-842161.","journal-title":"Blood"},{"issue":"2","key":"2872_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00277-018-3509-0","volume":"98","author":"OA Alkharabsheh","year":"2019","unstructured":"Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, et al. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Ann Hematol. 2019;98(2):331\u20137. https:\/\/doi.org\/10.1007\/s00277-018-3509-0.","journal-title":"Ann Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02872-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-02872-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02872-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T19:10:08Z","timestamp":1617390608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-02872-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02872-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"16 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that he has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient for the diagnostic and treatment procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}